Items tagged with Drug-sensitive TB
PAN-TB collaboration to advance investigational TB drug regimens to Phase 2 clinical trials (post)
Public-private collaboration to evaluate five antimicrobial agents across two combination regimens for treating both drug-susceptible and drug-resistant forms of TB with shorter treatment durations.
TB treatment can be cut to two months for some, finds landmark study (post)
Some cases of TB can be successfully treated in as little as two months – a third of the current standard of six months in South Africa and most other countries. This is according to early findings from the landmark TRUNCATE TB trial presented at 2022 Union World Conference on Lung Health.
Rifampicin dose escalation, higher starting dose helps patients with TB in ICU (post)
Dose escalation, guided by therapeutic drug monitoring, is an effective method to achieve target levels of rifampicin in those critically ill with TB.
Drug-susceptible TB: TB treatment strategy has potential to drastically slash therapy duration (TRUNCATE-TB trial) (post)
SEATTLE, February 22, 2023 -- An 8-week tuberculosis (TB) treatment strategy where additional therapy is reserved only for persistent disease or at relapse led to less overall treatment and similar clinical outcomes compared with the standard 6-month approach, an open-label randomized study showed.
Clinical trial for drug-sensitive and drug-resistant TB regimen evaluated shorter regimens (SimpliciTB trial) (post)
SEATTLE (February 20, 2023)—Results of TB Alliance’s SimpliciTB clinical trial were presented today at the 30th annual CROI 2023 conference. SimpliciTB was conducted to evaluate the BPaMZ regimen, consisting of bedaquiline (B), pretomanid (Pa), moxifloxacin (M), and pyrazinamide (Z). This combination previously showed high efficacy and treatment shortening potential in both preclinical evaluations and an early-stage clinical study in drug-resistant patients.
CROI 2023 TB research round up (post)
Treatment Action Group (TAG) released an overview of TB research data reported at the 30th Conference on Retroviruses and Opportunistic Infections (CROI 2023) held on 19-22 February 2023 in Seattle, Washington, USA. Highlights include the much-anticipated results of the SimpliciTB trial; additional analyses of the two-month TB treatment regimen studied in the TRUNCATE-TB trial; and the first clinical trial data on sutezolid since 2012.
What next after shortened TB treatment fails in key trial? (post)
Spotlight reflected on the results from two TB trials - SimpliciTB and TRUNCATE-TB, reported at the 30th Conference on Retroviruses and Opportunistic Infections (CROI 2023) held on 19-22 February 2023 in Seattle, Washington, USA, featuring TAG TB Co-Director Lindsay McKenna, elaborating on what comes next as an alternative to the six-month drug-susceptible standard of TB care.
PAN-TB collaboration announces the start of a Phase 2 clinical trial to evaluate two novel TB treatment regimens (post)
Public-private partnership launched a first-of-its-kind phase 2b/c trial to evaluate two novel tuberculosis drug regimens with the potential to treat all forms of active pulmonary TB
Drug-resistant TB responds rapidly to bedaquiline-based second-line therapy (post)
Patients who have drug-resistant tuberculosis (TB) have a similar microbiological response to bedaquiline-based second-line medications as patients with drug-sensitive TB taking first-line regimens, according to researchers at Weill Cornell Medicine in New York and GHESKIO in Haiti. Second-line medications are those that are given when one or more of the drugs given first for the disease are not effective. The research could have implications for shortening the duration of treatment for drug-resistant TB, which currently requires medications for up to 2 years, while those with drug-sensitive TB complete treatment in about 6 months.
Early program experience in the United States with four-month rifapentine and moxifloxacin–based TB treatment (post)
In 2020, a multicountry phase III randomized controlled clinical trial demonstrated the efficacy and safety of a 4-month regimen composed of isoniazid, rifapentine, moxifloxacin, and pyrazinamide (HPMZ) for the treatment of drug-sensitive TB.
Page 3 of 5 · Total posts: 0
←First 2 3 4 Last→